Holen Sie sich die Stockscreener-App
55.95
21.91%
-15.70
Handel nachbörslich:
58.41
2.46
+4.40%
Disc Medicine Inc Aktie (IRON) Neueste Nachrichten
FDA slaps CRL on Disc Medicine’s bitopertin NDA - The Pharma Letter
(IRON) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Disc Medicine stock slumps after FDA declines approval for inherited disorder drug over efficacy concerns - MSN
Disc Medicine (IRON) Drops 22% After FDA Response on Bitopertin - GuruFocus
Drug For Rare Genetic Disorder Goes From FDA Priority to Reject in Four Months - Bloomberg.com
Disc setback deepens questions about FDA’s accelerated approval commitment, value of new vouchers - biocentury.com
Disc Medicine plunges on FDA Complete Response Letter for bitopertin (IRON:NASDAQ) - Seeking Alpha
Disc Medicine Receives FDA Complete Response on Bitopertin - TipRanks
Breaking: US FDA’s Bitopertin CRL Shows CNPV Cannot Overcome Surrogate Endpoint Woes - Citeline News & Insights
FDA Issues Complete Response Letter to Bitopertin For Erythropoietic Protoporphyria - HCPLive
Disc Medicine EPP Treatment Fails to Get FDA Accelerated Approval - marketscreener.com
Disc Medicine (NASDAQ:IRON) Trading Down 40%What's Next? - MarketBeat
Disc Medicine stock plunges after FDA issues Complete Response Letter - Investing.com
FDA issues complete response letter for Disc Medicine’s EPP drug By Investing.com - Investing.com Canada
Disc Medicine Stock Slumps After FDA Declines Approval For Inherited Disorder Drug Over Efficacy Concerns - Stocktwits
Significant Drop for IronNet Stock (IRON) Amid Late-Day Trading - GuruFocus
FDA Responds to Bitopertin Application with Complete Response Letter - Intellectia AI
Disc Medicine Receives Complete Response Letter From FDA For Bitopertin For The Treatment Of EPP - TradingView
Disc Medicine plunges after FDA posts complete response letter for bitopertin - TipRanks
Disc Medicine confirms complete response letter from FDA for bitopertin - TipRanks
Disc Medicine (IRON) Addresses FDA Concerns with Confidence - GuruFocus
Disc Medicine Receives Complete Response Letter from FDA for Bitopertin for the Treatment of EPP - The Manila Times
US FDA declines to approve Disc Medicine's rare disease drug - Reuters
FDA Issues Complete Response Letter for Disc Medicine’s Bitopertin, Awaiting APOLLO Study Results for Potential Approval - Quiver Quantitative
FDA delays decision on rare disease drug, pushing verdict to 2027 - Stock Titan
Breakout Move: Is Disc Medicine Inc stock trending bullishWeekly Investment Recap & Community Driven Trade Alerts - baoquankhu1.vn
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, Inc.- IRON - PR Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Disc Medicine, Inc. (IRON) And Encourages Shareholders to Reach Out - ACCESS Newswire
2026-02-11 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Disc Medicine, Inc. (IRON) And Encourages Shareholders to Reach Out | NDAQ:IRON | Press Release - Stockhouse
Why retail investors favor Disc Medicine Inc. stockJuly 2025 Spike Watch & Safe Capital Preservation Plans - mfd.ru
2026-02-10 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Disc Medicine, Inc. (IRON) and Encourages Shareholders to Learn More About the Investigation | NDAQ:IRON | Press Release - Stockhouse
Disc Medicine, Inc. (IRON) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Disc Medicine, Inc. (NASDAQ:IRON) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
getLinesFromResByArray error: size == 0 - mfd.ru
Bronstein, Gewirtz & Grossman, LLC Is Investigating Disc Medicine, Inc. (IRON) And Encourages Investors to Connect - ACCESS Newswire
Hedge Fund Bets: Whats the beta of Disc Medicine Inc stockJuly 2025 Action & Entry Point Confirmation Alerts - baoquankhu1.vn
What Investors Should Know About a $511K Disc Medicine Insider Sale and a 26% Stock Run - AOL.com
Disc Medicine, Inc. (IRON) Investor Outlook: Unveiling a 51% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, ... - Bluefield Daily Telegraph
Trend Review: Will Disc Medicine Inc outperform during market rallies2025 Technical Overview & Daily Momentum Trading Reports - baoquankhu1.vn
Responsive Playbooks and the IRON Inflection - Stock Traders Daily
2026-02-01 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Disc Medicine, Inc. (IRON) And Encourages Stockholders to Connect | NDAQ:IRON | Press Release - Stockhouse
Atle Fund Management AB Purchases 21,038 Shares of Disc Medicine, Inc. $IRON - MarketBeat
Disc Medicine, Inc. (IRON) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - accessnewswire.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Disc Medicine, Inc. (IRON) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
BMO Capital reaffirms Disc Medicine stock rating amid approval optimism By Investing.com - Investing.com Canada
Bronstein, Gewirtz & Grossman, LLC Encourages Disc Medicine, Inc. (IRON) Investors to Inquire about Securities Investigation - accessnewswire.com
Y Intercept Hong Kong Ltd Purchases 33,905 Shares of Disc Medicine, Inc. $IRON - MarketBeat
Wall Street Analysts Believe Disc Medicine, Inc. (IRON) Could Rally 48.62%: Here's is How to Trade - Yahoo Finance
Disc Medicine, Inc. (IRON) Stock Analysis: Biotech Innovator With A 57% Upside Potential - DirectorsTalk Interviews
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Disc Medicine, Inc. (IRON) And Encourages Investors to Reach Out - ACCESS Newswire
Report of FDA Drug Approval Delay is 'Likely Noise': Analyst - streetwisereports.com
Pomerantz LLP Investigates Securities Fraud Claims Against Disc Medicine - Intellectia AI
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Disc Medicine, Inc. – IRON - Chartmill
Bear Alert: What is Disc Medicine Inc. s debt to equity ratioJuly 2025 Catalysts & Accurate Intraday Trade Tips - baoquankhu1.vn
HC Wainwright Weighs in on Disc Medicine FY2030 Earnings - MarketBeat
Disc Medicine and Sanofi reportedly face delays for FDA national priority review vouchers - MSN
iA Global Asset Management Inc. Raises Stock Holdings in Disc Medicine, Inc. $IRON - MarketBeat
Understanding the Setup: (IRON) and Scalable Risk - Stock Traders Daily
Disc Medicine (NASDAQ:IRON) Insider Rahul Khara Sells 1,000 Shares of Stock - MarketBeat
The Bull Case For Disc Medicine (IRON) Could Change Following FDA Review Delay And New HR Chief Appointment - Sahm
Disc Medicine, Sanofi, Eli Lilly Shares Slip On Reports Of FDA Increasing Review Time For Drugs Granted Priority Review Vouchers - Stocktwits
Is Disc Medicine Inc. attractive at current valuationWeekly Market Outlook & High Win Rate Trade Alerts - bollywoodhelpline.com
Assessing Disc Medicine (IRON) Valuation After FDA Review Delay And Heightened Regulatory Focus - Sahm
1.12%
0.87%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):